DAYBUE™ (trofinetide)

Acadia Pharmaceuticals has a worldwide exclusive licence from Neuren for trofinetide. On 10 March 2023 Acadia received marketing approval from the U.S. Food and Drug Administration (FDA) for DAYBUE™ (trofinetide) to treat Rett syndrome in adults and pediatric patients 2 years of age and older. Please refer to the ACADIA Pharmaceuticals website for further information about DAYBUE™ (trofinetide) in the United States.


Click here for Acadia's product information